Document:

English Translation of Technology Service Agreement

 Exhibit 4.33 
 Technology Service Agreement— 
 Diagnostic and Evaluation of
Students’ Learning System 
 V1.0 
 Party A: [Name of a school or subsidiary of New Oriental China] 
 Party B: Beijing Smart
Wood Technology Co., Ltd. 
  

	(1)	WHEREAS, Party A, a consulting company engaged in providing consulting services related to overseas study, needs Party B to provide it the development and daily
maintenance services of Diagnostic and Evaluation of Students’ Learning System V1.0; and 

  

	(2)	WHEREAS, Party B, a wholly owned foreign enterprise duly organized and existing under PRC laws, owns considerable ability in the software development technology and
hardware service technology fields, and possesses experience of the business associated therewith. 

 NOW, THEREFORE, through
friendly negotiation and on the principle of equality and mutual benefit, to the development and daily maintenance service of Diagnostic and Evaluation of Students’ Learning System V1.0 provided by Party B to Party A and the payments by Party A
for using Diagnostic and Evaluation of Students’ Learning System V1.0 under this agreement, Parties hereby agree as follows. 
  

	1.	General Rules 

  

	1.1	“Diagnostic and Evaluation of Students’ Learning System V1.0” means the diagnostic and evaluation of students’ learning system v1.0 software,
through independent R&D, designed and produced by professional staff organized by Party B within certain period and further developed according to Party A’s specific requirements, and legally used by Party A (the “System”).

  
 1 

	1.2	Responsibility of system development: under the premise of acquaintance to the business procedure of Party A, Party B shall organize professional staff to develop the
System in accordance with the business and function demands of Party A. Without written consent of Party A, Party B shall not assign the system development responsibility to any third party, in whole or in part. 

 

	1.3	System development term: upon the effectiveness of this Agreement, Party B shall fully complete the design and compilation of the System no later than [date]. Party B
shall obtain Party A’s confirmation and execute the plan confirmation letter; Party B shall fully finish the installment and adjustment, accept the checking and acceptance by Party A or the institution appointed by Party A no later than [date];
Party B shall assume unconditional obligations of amendment, upgrading or correction obligations in system functional defect, security defect and interface defect, if such defect still exists after the checking and acceptance.

  

	1.4	Maintenance and training of the System: Party B shall provide maintenance service to deal with system’s malfunctions in the using process by Party A; Party B shall
be responsible for the training of the System’s installment, using, daily maintenance and malfunction checking to Party A’s staff. 

  

	1.5	Ownership of the System: System is developed and accomplished by Party B. Party A and Party B jointly enjoy the rights of use of the System. 

 

	1.6	System expenses: means the usage fees and the fees for providing technology support and upgrading the system paid to Party B from Party A pursuant to this Agreement.

  

	2.	System Function 

  

	2.1	Under the premise of profound negotiation between Party A and Party B, Party A is responsible for communicating its demands to Party B, and Party B is responsible for
realizing system functions. 

  

	2.2	Final confirmation of system function shall be determined by the written documents acknowledged by Party A, including demanding analysis. Party B’s research and
collection of Party B’s demands and the documents associated therewith constitute the annex of this agreement, having legal effect together with this Agreement. 

  
 2 

	2.3	After the system has been checked, accepted and used normally by Party A, Party B may upgrade or expand the System under Party A’s commission for the purpose of
business expansion and alternation of Party A. 

  

	3.	System Defect 

  

	3.1	If there is any functional defect or operation interface defect in part after the System has been checked and accepted by Party A, Party A shall inform Party B in
writing. Party B shall respond within 24 hours after accepting the notice, and exclude the impediment unconditionally through amending, upgrading or correcting the program within the period confirmed by both parties at party B’s own expenses.
Party B shall be responsible for the damages of Party A thus caused. 

  

	3.2	If there is any data security defect existing after the system has been checked and accepted by Party A, Party B shall be liable pursuant to the provision of data
security responsibility in Article 7 of this Agreement. 

  

	4.	System Maintenance and Staff Training 

  

	4.1	In the course of normal using of the System by Party A, Party B shall resolve any system malfunction for reasons other than those provided in Article 3 of this
Agreement within 12 hours upon receipt of the notice. 

  

	4.2	Within 7 days after the system is checked and accepted by Party A, Party A shall start training at least one of its employees in the system’s installment, using,
daily maintenance and malfunction detection. Party A shall designate at least one employee to attend the training sessions. 

  

	4.3	After the system’s amendment, upgrading and correction, the parties must organize training sessions pursuant to Article 4.2 of this Agreement.

  

	5.	Intellectual Property and Source Code 

  
 3 

	5.1	Party B owns the whole intellectual property rights and the right of authorship of the System. 

 

	5.2	Party B possesses all the source codes of the System. 

  

	6.	System’s Checking and Acceptance 

  

	6.1	System shall be delivered to Party A from Party B for checking and acceptance no later than [date]. In the event that Party B delays in delivery, it shall pay Party A
liquidated damages equal to 1% of the contract price per day under this Agreement. In the event of a delay for over 30 days, Party A is entitled to reject acceptance. 

 

	6.2	System’s checking and acceptance can be conducted by either Party A or its designated institutions. 

 

	6.3	Party A shall appoint its employees to conduct checking and acceptance within 7 days upon the delivery by Party B. Checking and acceptance shall be deemed to have been
conducted by Party A if Party A fails to complete checking and acceptance within the 7-day period. 

  

	6.4	If the checking and acceptance delays or fails to pass for reasons provided in article 6.1 of this Agreement, Party A can terminate this Agreement. Party B shall refund
payments to Party A, and compensate the loss of Party A. 

  

	7.	Responsibility on Data Security 

  

	7.1	Party B shall ensure the System’s data security of Party A in the course of designing and developing of the System. Responsibilities on system data security
include but not limited to preventing illegal encroachment, preventing destruction of the System by computer virus, data recovery and back-up. 

  

	7.2	Party shall not be exempted from its liability for any encroachment to the System resulting from its adopting a third party’s software or hardware in its plan of
system data security design. 

  
 4 

	7.3	If there exists any data security defect after the System has been checked and accepted and such defect results in losses of Party A, within 24 hours upon the receipt
of Party A’s notice, Party B shall unconditionally exclude the impediment, recover the data and amend, upgrade or correct the data security system. Party A reserves the right to require Party B to compensate any and all of its losses.

  

	8.	Payment 

  

	8.1	Party A shall pay usage fees for the System to Party B in accordance with the revenues and profits generated from such System. 

 

	8.2	The usage fees for the System of this agreement after the checking and acceptance of Party A, is [percentage] of Party A’s monthly revenues. Party B has the right
to adjust the fee of using the System upon written notice to Party A at any time for any reason. Party A shall accept the adjusted fee in accordance with the Party B’s written notice. 

 

	8.3	Unless otherwise notified by Party B to Party A , the usage fees for the System under this agreement shall be paid on a quarterly basis, deposited by Party A to the
bank account designated by Party B, and Party B shall issue formal invoice to Party A. 

  

	8.4	Tax and expenses arising out of the execution and implement of this agreement shall be borne by both parties. 

 

	9.	Liability for Breach of Contract 

  

	9.1	In the event that Party A assigns the use right of using the System provided hereunder to a third party without consent of Party B, Party B is entitled to request Party
A to stop infringing acts and indemnify Party B and hold Party B harmless. Party A shall compensate twice of its profit generated from such infringement to Party B, Party B reserves its right to take any legal actions. 

 

	9.2	In the event that Party B breaches this agreement and causes losses and damages to Party A’s teaching operation, Party B shall compensate Party A twice of its
losses. 

  
 5 

	9.3	In the event that Party A fails to pay the fees provided under this agreement to Party B in time, it shall pay to Party B liquidated damages equal to 0.05% of the
overdue payment per day. When overdue for thirty (30) days, Party B shall have the right to terminate this Agreement. 

  

	10.	Term and Termination 

  

	10.1	The term of this Agreement shall be [period], commencing from the date of effectiveness of this Agreement. Unless otherwise notified by Party B to Party A to terminate
this Agreement, this Agreement shall be renewed for two (2) years automatically. The times of renewal shall be unlimited. Party B may terminate this Agreement at any time. Without the consent of Party B, Party A shall not terminate this
Agreement. 

  

	10.2	Any Party will be deemed breaching of contract if it fails to perform any obligation hereunder; the non-breaching party is entitled to issue a written notice of
termination of this agreement to the breaching party if the breach is not cured or remedied by the breaching party within sixty (60) business days upon the issuance of the written notice, and under such circumstance this Agreement may be
terminated thereafter. If the breach is cured within sixty (60) business days upon the issuance of the written notice, this Agreement will remain effective. 

 

	11.	Dispute Resolution 

  

	11.1	The Parties shall use their best efforts in good faith to amicably settle any dispute arising out of the performance of this agreement. If the parties fail to reach a
settlement agreement, any party can submit the disputes to Beijing Arbitration Commission for arbitration in Beijing in accordance with its rules of arbitration in effect. The arbitral award shall be final and binding upon both parties.

  

	11.2	“Dispute” in this clause means the dispute to the formation, time of formation, interpretation, performance, default liability, and modification, assignment,
termination and expiry of this Agreement. 

  
 6 

	12.	Miscellaneous 

  

	12.1	This Agreement shall become effective upon the date of execution by both parties. The Parties hereto may enter supplement contracts to the matters not mentioned herein
through negotiation. Supplement contracts shall have equal effect to this Agreement. 

  

	12.2	Any provision of this Agreement shall be deemed as severable in a jurisdiction where it conflicts to the laws in this jurisdiction. Any unenforceability of a provision
in a jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 

  

	12.3	This Agreement together with the documents incorporated hereinto constitutes the full and entire understanding and agreement among the Parties with regard to the
subjects hereof and thereof. Except for those specifically set forth herein or therein, the Parties are not bound by any other conditions, provisions, warranties or representations. 

 

	12.4	Any amendments to this Agreement shall be made in written and shall become effect after the signing and stamping by authorized representatives of both Parties. Such
amendments shall have the same effect to this Agreement. 

  

	12.5	The execution, validity, construction, performance, modification and dispute resolution of this Agreement will be governed by PRC laws. 

 

	12.6	Party A shall not assign this Agreement, in part or in whole, to any third party without the prior consent of Party B. 

 

	12.7	A party’s failure to require the other party to fully and timely perform any provision of this Agreement shall not be deemed as its wavier to require the other
party’s performance of this provision at any time thereafter. 

  
 7 

	12.8	If a force majeure event affects the performance of this Agreement, the affected party shall immediately notify the other Party by means of telegraph, fax or other
electronic forms, and shall furnish within fifteen (15) days thereafter sufficient evidence of the occurrence of the force majeure event. According to impact of the force majeure event to the performance of this agreement, the parties shall
determine whether to terminate this agreement through negotiation, waive the performance responsibility in part, or postpone the performance. 

  

	12.9	Unless otherwise provided under this Agreement, a “day” means a calendar day, and a “business day” means the normal business day of commercial banks
in China. 

  

	12.10	The annexes of this Agreement shall be considered as an integral part of this Agreement, and have the same effect as this Agreement. 

 

	12.11	This Agreement is executed in three originals with each party holding one and the third one being filed with Technology Market. 

Each party has caused this agreement to be effective from the date of [date]: 
 Party A: [Name of a school or subsidiary of New Oriental China] 
 Authorized representative
(signature): /s/ authorized signatory or seal              
 Party B:
Beijing Smart Wood Software Technology Co., Ltd. 
 Authorized representative (signature): /s/ authorized signatory or seal
             

  
 8 

 Schedule of Material Differences 

One or more schools or subsidiaries of New Oriental China entered into technology service agreement—diagnostic and evaluation of students’
learning system v1.0 using this form. Pursuant to instruction ii to Item 601 of Regulation S-K, the Registrant may only file this form as an exhibit with schedule setting forth the material details in which the executed agreements differ from
this form: 
  

							
	 Party A
	  	Date of
Effectiveness	  	Fee (% of Party A’s
Revenues)	 
	 Beijing New Oriental Vision Overseas Consultancy Co., Ltd.
	  	12/21/2011	  	 	5	% 

  
 9Termination Agreement and Waiver, dated October 5,2012

 Exhibit 10.1 
 KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT 

AND WAIVER 

This TERMINATION AGREEMENT AND WAIVER (this “Agreement”) is entered into as of October 5, 2012, by and among KaloBios
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the undersigned holders of the Company’s capital stock (the “Holders”). 
 WHEREAS, the Company intends to offer, issue and sell shares of the Company’s common stock (the “Shares”) in an initial public offering (the “Offering”) and intends to undertake a
registration of the Shares (the “Registration”) by preparing, executing and filing with the Securities and Exchange Commission a registration statement on Form S-1 (the “Registration Statement”) under the Securities Act of
1933, as amended (the “Act”); 
 WHEREAS, the Company and certain of the Holders are parties to that certain Amended
and Restated Investors’ Rights Agreement, dated as of May 2, 2012 (the “Rights Agreement”), which grants the Holders, among other things, certain notice and registration rights in connection with the Registration; 

WHEREAS, pursuant to Section 1.3(a) of the Rights Agreement if the Company proposes to register any of its stock or other securities
pursuant to the Act in connection with the public offering of such securities, subject to certain exceptions, the Company is obligated to promptly give written notice to all Holders (as defined in the Rights Agreement) of such registration, and the
Company shall, subject to certain exceptions, use best efforts to cause to be registered under the Act all of the Registrable Securities (as defined in the Rights Agreement) that each such Holder has requested to be registered; 

WHEREAS, pursuant to Section 1.3(c) of the Rights Agreement upon the effectiveness of the Company’s first Form 10 registration
statement, the Company shall, among other obligations, (i) use its reasonable best efforts to file a registration statement on Form S-1 covering the resale, among other securities, of the shares of Common Stock issued or issuable upon
conversion of the shares of the Company’s Preferred Stock and (ii) use its reasonable best efforts to cause its Common Stock, including all Re-Sale Shares (as defined in the Rights Agreement), to be quoted on an OTC Quotation System and,
if otherwise eligible pursuant to applicable listing requirements, to be listed on a national securities exchange as soon as practicable following the Company’s acceptance for quotation on an OTC Quotation System; 

WHEREAS, pursuant to Sections 2.1 through 2.7 and Section 3.10 of the Rights Agreement the Company has is obligated to perform
certain obligations to its Investors including, but not limited to, delivering financial statements, providing certain information rights, providing a right of first offer with respect to sales of its Shares (as defined in the Rights Agreement),
implement certain vesting provisions on its grants of stock options, maintain certain insurance policies, hold meetings of its Board of Directors at least bimonthly and pay the 

 
reasonable out of pocket expenses of all Directors (as defined therein) in attending all meetings of the Board of Directors and committees thereof and performing their duties as Directors;

 WHEREAS, pursuant to Section 2.9 of the Rights Agreement the Company is restricted from taking certain actions without
the express prior written consent of the Fidelity Investors (as defined in the Rights Agreement); 
 WHEREAS, pursuant to
Section 2.10 of the Rights Agreement the Company is obligated to, among other things, use its commercially reasonable efforts to cause the managing underwriters of its Initial Public Offering (as defined in the Rights Agreement), if such
Initial Public Offering is consummated at least one (1) year after the date of the Rights Agreement, to designate a number of shares equal to five percent (5%) of the Common Stock to be offering in such Initial Public Offering for sale
under a “directed share program”; 
 WHEREAS, the Holders, including, without limitation, the Fidelity Investors,
desire to facilitate a successful Offering by (i) waiving all notice and registration rights provided in Sections 1.3(a) and 1.3(c) (and to the extent applicable Section 1.5) of the Rights Agreement in connection with the Registration,
(ii) effective upon the consummation of the Offering, terminating the covenants contained in Sections 2.1 through 2.7, Section 2.9 and Section 3.10 of the Rights Agreement, and (iii) acknowledging that Section 2.10 shall not
apply to the Offering and waiving all notice and rights thereunder with respect to the Offering. 
 WHEREAS, the Company and
certain of the Holders are parties to that certain Amended and Restated Right of First Refusal and Co-Sale Agreement, dated as of May 2, 2012 (the “Co-Sale Agreement”); 

WHEREAS, the Company and certain of the Holders are parties to that certain Amended and Restated Voting Agreement, dated as of
May 2, 2012 (the “Voting Agreement”); 
 WHEREAS, the Holders desire to facilitate a successful Offering by
terminating the Co-Sale Agreement and the Voting Agreement, contingent upon and effective immediately prior to the consummation of the Offering; 
 WHEREAS, the Holders understand that the Company and the underwriters of the Offering will proceed with the Offering in reliance on this Agreement; 

WHEREAS, Section 3.7 of the Rights Agreement provides that any term of the Rights Agreement (other than Section 2.1 and
Section 2.9) may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the holders of at least sixty-percent (60%) of the Registrable
Securities (as defined therein); provided, however, that any amendment that adversely and disproportionately affects the shares of Series E Preferred Stock (or shares of Common Stock issuable upon conversion thereof) in a manner different than the
other series of Preferred Stock or the Common Stock shall require the prior written consent of the holders of at least sixty percent (60%) of the then outstanding shares of Series E Preferred Stock; 

  
 2 

 WHEREAS, any amendment, modification, termination or waiver of Section 2.1 (as so far
as it relates to the rights of the Fidelity Investors thereunder) and 2.9 of the Rights Agreement shall require the express prior written consent of the Fidelity Investors; 
 WHEREAS, Section 9 of the Co-Sale Agreement provides that the Co-Sale Agreement shall terminate and be of no further force or effect upon the date specified by written consent or agreement of the
holders of not less than sixty percent (60%) of the then outstanding Preferred Shares (as defined therein); and 
 WHEREAS,
Section 14 of the Voting Agreement provides that the Voting Agreement shall terminate and be of no further force or effect upon the date specified by written consent or agreement of the holders of a majority of the outstanding Common Stock held
by the Common Holders (as defined therein) and the holders of not less than sixty percent (60%) of the outstanding shares of Preferred Stock. 
 NOW, THEREFORE, the parties hereto hereby agree as follows: 
 1. Waiver of
Notice and Registration Rights under Section 1.3(a). Pursuant to Section 3.7 of the Rights Agreement, the Holders hereby waive (a) any and all rights (including all notice rights related thereto) to include in the Registration any
Registrable Securities held by the Holders in the Offering provided under Section 1.3(a) of the Rights Agreement (including any rights under Section 1.5 of the Rights Agreement) and (b) any noncompliance by the Company with the
procedures called for by the Rights Agreement with respect to Section 1.3(a). 
 2. Waiver of Section 1.3(c).
Pursuant to Section 3.7 of the Rights Agreement, the Holders hereby waive any noncompliance by the Company with the procedures called for by the Rights Agreement under Section 1.3(c) relating to the Company’s obligation to use its
reasonable best efforts to file a Registration Statement on Form S-1 covering the resale of the Re-Sale Shares (as defined in the Rights Agreement) provided that such waiver shall no longer be effective after June 30, 2013 if the Offering has
not been consummated by such date. 
 3. Acknowledgment and Waiver of Directed Share Obligations. The Holders hereby
acknowledge that Section 2.10 of the Rights Agreement shall not apply to the Offering, so long as the Offering is consummated prior to May 2, 2013. In addition, pursuant to Section 3.7 of the Rights Agreement, the Holders hereby waive
all obligations of the Company in connection with the Offering as set forth in Section 2.10 of the Rights Agreement, including, without limitation, the Company’s obligation to use its commercially reasonable efforts to cause the managing
underwriter(s) of the Offering to designate a number of shares for sale under a “directed shares program.” 
 4.
Termination of Covenants in Rights Agreement. Pursuant to Section 3.7 of the Rights Agreement (and Section 2.9 of the Rights Agreement pursuant to the rights of the Fidelity Investors), the Company and the Holders (including the
Fidelity Investors (as defined therein)) hereby acknowledge and agree that, contingent upon and effective immediately prior to the consummation of the Offering, the covenants set forth in Section 1.3(c), Sections 2.1 through

  
 3 

 
2.7, Section 2.9 and Section 3.10 of the Rights Agreement shall be terminated and of no further force and effect. 

5. Continued Validity of Rights Agreement. Except as waived or terminated hereby, the Rights Agreement shall continue in full
force and effect as originally constituted. 
 6. Termination of Co-Sale Agreement. Pursuant to Section 9 of the
Co-Sale Agreement, the Company and the Holders hereby acknowledge and agree that, contingent upon and effective immediately prior to the consummation of the Offering, the Co-Sale Agreement and all rights and obligations of all parties thereunder
shall be terminated, any post-termination rights which would otherwise survive termination shall be terminated and the Co-Sale Agreement shall be null and void and of no effect whatsoever. 

7. Termination of Voting Agreement. Pursuant to Section 14 of the Voting Agreement, the Company and the Holders hereby
acknowledge and agree that, contingent upon and effective immediately prior to the consummation of the Offering, the Voting Agreement and all rights and obligations of all parties thereunder shall be terminated, any post-termination rights which
would otherwise survive termination shall be terminated and the Voting Agreement shall be null and void and of no effect whatsoever. 
 8. Counterparts. This Waiver may be executed in two or more counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.

 9. Governing Law. This Waiver shall be governed by and construed under the laws of the State of California as applied
to agreements among California residents entered into and to be performed entirely within California. 
 [Remainder of page
intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

					
		 	 KALOBIOS PHARMACEUTICALS, INC.

			
		 	By:	 	 /s/ David Pritchard

		 	Name:	 	David Pritchard
		 	Title:	 	Chief Executive Officer

  

			
	 Address:
	 	 260 East Grand Avenue

South San Francisco, CA 94080

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

	
	
	 /s/ David Pritchard

	David Pritchard

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

	
	
	 /s/ Geoffrey Yarranton

	Geoffrey Yarranton

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	MPM BIOVENTURES III, L.P.
		
	By:	 	 MPM BioVentures III GP, L.P.,

its General Partner

	By:	 	 MPM BioVentures III LLC,
 its
General Partner

		 	
	By:	 	 /s/ Dennis Henner

	Name:	 	Dennis Henner
	Title:	 	Series A Member
	
	MPM BIOVENTURES III-QP, L.P.
		
	By:	 	 MPM BioVentures III GP, L.P.,

its General Partner

	By:	 	 MPM BioVentures III LLC,
 its
General Partner

		
	 By:
	 	 /s/ Dennis Henner

	 Name:
	 	Dennis Henner
	 Title:
	 	Series A Member
	
	MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG
		 	
	By:	 	 MPM BioVentures III GP, L.P., in its
 capacity as the Managing Limited Partner

		
	By:	 	 MPM BioVentures III LLC,
 its
General Partner

		
	 By:
	 	 /s/ Dennis Henner

	 Name:
	 	Dennis Henner
	 Title:
	 	Series A Member

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	MPM BIOVENTURES III PARALLEL FUND, L.P.
		
	By:	 	MPM BioVentures III GP, L.P., its General Partner
	By:	 	MPM BioVentures III LLC,its General Partner

  

			
	By:	 	 /s/ Dennis Henner

	Name:	 	Dennis Henner
	Title:	 	Series A Member

  

			
	MPM ASSET MANAGEMENT INVESTORS 2005 BVIII LLC
		
	By:	 	 /s/ Dennis Henner

	Name:	 	Dennis Henner
	Title:	 	Manager

  

			
	MPM BIOVENTURES STRATEGIC FUND, L.P.
		
	By:	 	MPM BioVentures III GP, L.P., its General Partner
	By:	 	MPM BioVentures III LLC, its General Partner

  

			
		
	By:	 	 /s/ Dennis Henner

	Name:	 	Dennis Henner
	Title:	 	Series A Member

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	SOFINNOVA VENTURE PARTNERS V, LP
	By:	 	Sofinnova Management V 2005, LLC
	Its General Partner
		
	By:	 	 /s/ James I. Healy

		 	James I. Healy, Managing Director

  

			
	SOFINNOVA VENTURE AFFILIATES V, LP
	By:	 	Sofinnova Management V, LLC
	Its General Partner
		
	By:	 	 /s/ James I. Healy

		 	James I. Healy, Managing Director

  

			
	SOFINNOVA VENTURE PRINCIPALS V, LP
	By:	 	Sofinnova Management V, LLC
	Its General Partner
		
	By:	 	 /s/ James I. Healy

		 	James I. Healy, Managing Director

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	ALLOY PARTNERS 2000, L.P.
	ALLOY VENTURES 2000, L.P.
	ALLOY CORPORATE 2000, L.P.
	ALLOY INVESTORS 2000, L.P.

  

			
	 By:
	 	Alloy Ventures 2000, LLC,
	 its General Partner

  

	
	 /s/ Tony Di Bona

	 Managing Member of

	 Alloy Ventures 2000, LLC

  

			
	ALLOY ANNEX I, L.P.
		
	 By:
	 	 Alloy Annex I, LLC

	 its General Partner

 
	
	
	 /s/ Tony Di Bona

	 Managing Member of

	 Alloy Annex I, LLC

  

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	5AM VENTURES LLC
		
	By:	 	 /s/ Andrew Schwab

		
	Name:	 	 Andrew Schwab

		
	Title:	 	 Managing Partner

	
	5AM CO-INVESTORS LLC
		
	By:	 	 /s/ Andrew Schwab

		
	Name:	 	 Andrew Schwab

		
	Title:	 	 Managing Partner

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

					
	Signed for and on behalf of GBS Venture Partners Limited (ABN 54 072 515 247) in its capacity as trustee of GBS BioVentures II
			
	 /s/ Brigitte Smith
	 		 	 /s/ Susan Wolf

	Director	 		 	 Company Secretary

			
	 Brigitte Smith
	 		 	 Susan Wolf

	Name	 		 	Name
	
	Signed for and on behalf of GBS Venture Partners Limited (ABN 54 072 515 247) in its capacity as trustee of the Genesis Fund
			
	 /s/ Brigitte Smith
	 		 	 /s/ Susan Wolf

	Director	 		 	 Company Secretary

			
	 Brigitte Smith
	 		 	 Susan Wolf

	Name	 		 	Name

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	GENZYME CORPORATION
		
	By:	 	 /s/ David Meeker

		
	Name:	 	 David P. Meeker

		
	Title:	 	 President and CEO

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	BAXTER INTERNATIONAL INC.
		
	By:	 	 /s/ Stephanie Shinn

		
	Name:	 	 Stephanie Shinn

		
	Title:	 	 Corporate Vice President and
Corporate Secretary

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	FIDELITY MAGELLAN FUND:
FIDELITY MAGELLAN FUND
		
	By:	 	 /s/ Joseph Zambello

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

	
	FIDELITY SELECT PORTFOLIOS: BIOTECHNOLOGY PORTFOLIO
		
	By:	 	 /s/ Joseph Zambello

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

	
	FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR BIOTECHNOLOGY FUND
		
	By:	 	 /s/ Joseph Zambello

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

	
	VARIABLE INSURANCE PRODUCTS
FUND III: BALANCED PORTFOLIO
		
	By:	 	 /s/ Joseph Zambello

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	 FIDELITY ADVISOR SERIES I:
 FIDELITY ADVISOR DIVIDEND GROWTH FUND

		
	By:	 	 /s/ Joseph Zambello

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

  

			
	 FIDELITY SECURITIES FUND:
 FIDELITY DIVIDEND GROWTH FUND

		
	By:	 	 /s/ Joseph Zambello

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

  

			
	FIDELITY RUTLAND SQUARE TRUST II: STRATEGIC ADVISERS CORE MULTI-MANAGER FUND
		
	By:	 	 /s/ Joseph Zambello

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

  

			
	FIDELITY RUTLAND SQUARE TRUST II: STRATEGIC ADVISERS CORE FUND
		
	By:	 	 /s/ Joseph Zambello

		
	Name:	 	 Joseph Zambello

		
	Title:	 	 Deputy Treasurer

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

			
	Mitsubishi UFJ Capital II, Limited partnership
	by: Mitsubishi UFJ Capital its General Partner

  

			
	 By:
	 	 /s/ Yoshihiro Hashimoto

	 Name:
	 	Yoshihiro Hashimoto, President
	 Title:
	 	President

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first
set forth above. 
  

	
	
	 /s/ Claire N. Baer

	Claire N. Baer

  

KALOBIOS PHARMACEUTICALS, INC. 
 TERMINATION AGREEMENT AND WAIVER

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]